ODI Pharma AB (publ) reported earnings results for the third quarter and nine months ended March 31, 2023. For the third quarter, the company reported sales was SEK 0.010801 million compared to SEK 0.071298 million a year ago. Revenue was SEK 0.024544 million compared to SEK 0.064812 million a year ago. Net loss was SEK 0.944121 million compared to SEK 2.34 million a year ago. Basic loss per share from continuing operations was SEK 0.06 compared to SEK 0.15 a year ago.
For the nine months, sales was SEK 0.112083 million compared to SEK 0.529918 million a year ago. Revenue was SEK 0.15093 million compared to SEK 0.581897 million a year ago. Net loss was SEK 4.37 million compared to SEK 4.92 million a year ago. Basic loss per share from continuing operations was SEK 0.29 compared to SEK 0.32 a year ago.